March 25th 2025
Chichi Ilonzo Momah, PharmD, discussed what pharmacists can be doing to address vaccine hesitancy and the barriers impeding under-resourced communities.
NACDS Total Store Expo offers four-day event for retailers, suppliers
August 7th 2013NACDS' Total Store Expo, opening at the Sands Expo and Convention Center in Las Vegas, on Saturday, August 10, brings together its Marketplace Conference, its Pharmacy & Technology Conference, and its Supply Chain & Logistics Conference.
Committee calls for Senate action on updated compounding bill
July 29th 2013The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee called for the Senate to act on its bill to provide clear oversight of compounding manufacturers, following the 2012 fungal meningitis outbreak, and to protect the U.S. drug supply chain from counterfeiting and theft, according to a HELP Committee statement on July 25.
Three things pharmacists should know about Ramadan
July 22nd 2013Many Muslims in America recently began their annual celebration of Ramadan, which for many includes fasting or long stretches without eating or drinking. This year, Ramadan began on July 9th and will end on August 7th. For Muslims with chronic illnesses, this can present significant risks.
Prevention of heart attacks by targeting CVD patients
July 15th 2013Face-to-face interaction between pharmacists and patients will be key to the success or failure of the federal government’s Million Hearts initiative to prevent heart attacks and strokes, Salvatore Giorgianni, PharmD, told participants during the June 3 State of Men’s Heart Webinar.
FDA advisers recommend easing Avandia restrictions
July 15th 2013FDA advisers recommended in early June the easing of restrictions on the diabetes drug rosiglitazone (Avandia, GlaxoSmithKline), following an independent re-examination of GSK’s RECORD study conducted by Duke Clinical Research Institute.
Long-term data reinforce safety profile of dabigatran
July 15th 2013Results from the RELY-ABLE trial, the RE-LY extension study, support the long-term safety profile of dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) 150 mg twice daily in patients with nonvalvular atrial fibrillation (NVAF), according to a study published in Circulation in mid-June.